Showing 11-20 of 58 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Targeting Complement-Driven Antigen Presentation in Tertiary Lymphoid Structures to Prevent Type 1 Diabetes | The Regents of the University of California, San Francisco | Anil Bhushan | Cures | 01-September-2026 to 31-August-2028 | $498.142,00 |
| Local delivery of immunomodulators to enable systemic immunosuppression-free efficient islet transplantation | The Regents of the University of California, San Francisco | Bhushan Kharbikar | Cures | 01-March-2024 to 28-February-2027 | $215.604,64 |
| Reducing Diabetes Distress in Adults with Type 1 Diabetes: A pragmatic trial in routine diabetes care. | The Regents of the University of California, San Francisco | Danielle Hessler | Improving Lives | 01-August-2023 to 14-September-2027 | $1.743.010,00 |
| Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) | The Regents of the University of California, San Francisco | Feroz Papa | Cures | 01-August-2023 to 31-July-2027 | $960.000,00 |
| Creation of a single-cell derived shared autoimmune framework for the study of SLE, T1D, and MS | The Regents of the University of California, San Francisco | Gabriela Fragiadakis | Cures | 01-September-2026 to 31-August-2027 | $150.000,00 |
| Identification of novel targets to increase human beta cell proliferation | The Regents of the University of California, San Francisco | Gregory Ku | Cures | 01-December-2020 to 31-August-2026 | $975.000,00 |
| Sequential multi-molecule release from nanofiber scaffolds for improved stem cell-derived islet transplantation under the skin | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2028 | $845.444,86 |
| Mesh Oxygen Transporter for improved engraftment of human stem cell-derived pancreatic islet cells in the subcutaneous site | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 30-June-2027 | $294.796,07 |
| Generation of vascularized, transplantable islets from human iPSC-derived beta and isogenic vasculogenic cells | The Regents of the University of California, San Francisco | Julie Sneddon | Cures | 01-July-2024 to 30-June-2026 | $599.999,99 |
| Assessing Beta Cell Fragility in STAT1 Gain-of-Function Diabetes | The Regents of the University of California, San Francisco | Martin Thelin | Cures | 01-July-2026 to 30-June-2027 | $50.000,00 |